Lowest Price Guaranteed From USD 4,899
The single cell sequencing market is estimated to be worth $1,387 million in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 15% during the forecast period. Over the years, technological advances in the field of genomics have enabled pharma companies to adopt a more personalized and targeted approach to drug / therapy development. Specifically, next-generation sequencing (NGS) technologies have enabled millions of human genomes across diverse ethnicities, to be sequenced. The large volumes of genomic data from the aforementioned sequencing studies have led to the generation of valuable insights on individuals' likely responses to different treatment regimens. Innovation in this field have made NGS technologies increasingly affordable and accessible. In fact, the cost of sequencing a single genome has dropped from USD ~3 billion (Human Genome Project 1990) to USD 1,000 (Illumina sequencing kits) over the last two decades. However, NGS based analyses are limited to offering averaged insights on gene expression. In other words, this method is incapable of quantifying nucleic acid content in individual cells, and thereby, offering gene expression information at single cell resolution. To better understand the interactions of individual cells with their microenvironment, advanced molecular probing solutions are required. In this context, high-throughput single cell analysis, an emerging analytical technique, is considered a powerful means for studying individual cells, enabling researchers to study gene expression at single cell resolution.
Single cell technologies offer many advantages over traditional genomic analyses, enabling the detection of complex and rare cell populations, and elucidating development trajectories of distinct cell lineages. Despite the potential to be used across diverse segments in biotechnology and medical research, single cell technologies are still limited to early-stage research activities. This is primarily attributed to certain challenges associated with data processing and quality control. Further, the lack of versatile in silico tools is also considered among the major roadblocks to meaningful analysis and interpretation of single cell sequencing data. Additionally, the high cost of process execution and affiliated labor intensive protocols are other barriers to the adoption of since-cell sequencing technology. However, the introduction of the RNA-QC-Chain tool in 2018 (an effort to address the data processing and quality control related challenges) and the Human Cell Atlas project (responsible for developing the first whole transcriptome map of human cells), are considered prominent milestones in the field of single cell genomics. Presently, experts believe that the single cell analysis market in North America, may reach USD 5 billion by 2025. Given, the potential of single-cell RNA sequencing (scRNA-seq) technologies to probe into previously unelucidated cellular mechanisms, and identify novel biomarkers / therapeutic targets, they are likely to witness significant market growth and adoption in biomedical research during the forecast period.
Examples of key single cell companies engaged in single cell sequencing market (which have also been profiled in this market report; the complete list of single cell companies is available in the full report) include Active Motif, Admera Health, Annoroad Genomics, BGI Genomics, CD Genomics, MedGenome, Quick Biology, SingulOmics, 10x Genomics, Cell Microsystems, Fluidigm, Illumina, Mission Bio and Oxford Nanopore Technologies. This market report includes an easily searchable excel database of all the single cell companies, worldwide.
Several recent developments have taken place in the field of single cell sequencing market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Single Cell Sequencing Market, 2020-2030’ market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the single cell sequencing market.
In addition to other elements, the market research report features:
The key objective of single cell sequencing market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for single cell analysis market during the forecast period. Based on several parameters, such as number of single-cell samples sequenced annually, average cost of sequencing, and growth trends across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the forecast period 2020-2030. The chapter features the likely distribution of the opportunity across different [A] key market segments (services and technologies), [B] type of system (sequencing and workflow instruments), [C] end-user (pharmaceutical companies, academic and research institutions and other end-users), [D] area of application (diagnostics, drug discovery, precision medicine and others) and [E] geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in this market research report were influenced by discussions conducted with multiple stakeholders in single cell sequencing market.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD, unless otherwise specified.